Provided by Tiger Trade Technology Pte. Ltd.

Entrada Therapeutics, Inc.

7.30
+0.23003.25%
Post-market: 7.300.00000.00%19:30 EDT
Volume:306.54K
Turnover:2.20M
Market Cap:283.39M
PE:-1.84
High:7.34
Open:7.07
Low:6.96
Close:7.07
52wk High:16.45
52wk Low:5.02
Shares:38.82M
Float Shares:22.56M
Volume Ratio:1.23
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9676
EPS(LYR):-3.4746
ROE:-54.09%
ROA:-29.20%
PB:1.21
PE(LYR):-2.10

Loading ...

Entrada Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
5 hours ago

MPM BioVentures 2014 Reports $612,948 Entrada Therapeutics Common Share Sale

Reuters
·
Sep 01

MPM BioVentures 2018 Reports Entrada Therapeutics Common Stock Disposal Worth $471,391.64

Reuters
·
Aug 27

Major Insider Moves Shake Up Entrada Therapeutics Inc. Stock

TIPRANKS
·
Aug 11

5AM Ventures V Reports Entrada Therapeutics Share Disposal Worth $431,620

Reuters
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Janux Therapeutics Inc (JANX) and Entrada Therapeutics Inc (TRDA)

TIPRANKS
·
Aug 10

NextCure Q2 Net Loss Narrows on Lower Expenses

Reuters
·
Aug 07

PepGen Q2 Net Loss Narrows as Expenses Fall

Reuters
·
Aug 06

Biomea Fusion Q2 Loss Narrows, Cash Runway into Q2 2027

Reuters
·
Aug 06

Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge

Reuters
·
Aug 06

Editas Medicine Q2 Net Loss Narrows and Beats Estimates

Reuters
·
Aug 06

Black Diamond Therapeutics Q2 Net Loss Narrows Year over Year

Reuters
·
Aug 06

Entrada Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Entrada Therapeutics Publishes Corporate Presentation on Genetic Medicines Pipeline for Neuromuscular and Inherited Retinal Diseases

Reuters
·
Aug 05

Entrada Therapeutics Q2 EPS $(1.01) Beats $(1.09) Estimate, Sales $898.000K Beat $411.429K Estimate

Benzinga Earnings
·
Aug 05

Entrada Therapeutics Q2 Net Loss Narrows on Lower Costs

Reuters
·
Aug 05

Entrada Therapeutics, Inc. Q2 Income from Operations USD -44.963 Million

THOMSON REUTERS
·
Aug 05

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 05

Entrada Therapeutics Director, 10% Owner Kush Parmar Disposes of $807,529 in Common Shares

Reuters
·
Aug 04

Entrada Therapeutics Inc Expected to Post a Loss of $1.05 a Share - Earnings Preview

Reuters
·
Jul 31